)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Grand Pharmaceutical Group (512) investor relations material
Grand Pharmaceutical Group H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary19 Aug, 2025
Executive summary
Revenue for the six months ended 30 June 2025 grew 1.0% year-over-year to HK$6,107.32 million, with innovative and barrier products accounting for 51.0% of total revenue, up 14.9 percentage points year-over-year.
Net profit attributable to owners was HK$1,169.02 million, down 25.0% year-over-year, mainly due to lower gains from Telix investment and increased marketing expenses for new products.
Excluding Telix investment impact, normalized profit declined 5.9% year-over-year, primarily from centralized procurement price reductions and higher marketing costs.
The Group maintained strong R&D investment and global expansion, with 133 projects under research and 42 innovation projects across multiple therapeutic areas.
Strategic acquisitions in medical devices and traditional Chinese medicine expanded the product pipeline and market competitiveness.
Financial highlights
Revenue: HK$6,107.32 million (+1.0% YoY); in RMB terms, +2.0% YoY; excluding centralized procurement, +13.0% YoY.
Net profit attributable to owners: HK$1,169.02 million (-25.0% YoY); normalized profit: HK$1,017.29 million (-5.9% YoY).
Gross profit: HK$3,600.16 million (flat YoY); EPS: 33.38 HK cents (vs. 44.41 HK cents last year).
Distribution costs: HK$1,916.29 million (+19% YoY); administrative expenses: HK$691.75 million (+14% YoY); finance costs: HK$80.35 million (down from HK$86.12 million).
R&D and project investment: HK$1,022 million for the period.
Cash and cash equivalents: HK$479.10 million as of 30 June 2025.
Outlook and guidance
The Group will continue to focus on innovation-driven growth, global expansion, and product pipeline optimization.
Emphasis on advancing blockbuster products like STC3141 and YiGanTai® for sepsis and expanding the nuclear medicine portfolio globally.
Ongoing investment in R&D and international clinical trials to accelerate commercialization of innovative drugs.
The Group aims to strengthen its global presence and maintain high R&D investment to support sustainable development.
How did centralized procurement impact revenue?
Discuss progress of STC3141 development.
Elaborate on global nuclear medicine expansion.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Grand Pharmaceutical Group earnings date
H2 202518 Mar, 2026
Next Grand Pharmaceutical Group earnings date
H2 202518 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Grand Pharmaceutical Group Limited is a healthcare company engaged in the research, development, manufacturing, and distribution of pharmaceutical and medical products. The company specializes in prescription drugs, biopharmaceuticals, medical devices, and consumer healthcare products, serving therapeutic areas such as cardiovascular, respiratory, oncology, and ophthalmology. The company is headquartered in Wuhan, China, and its shares are listed on the Hong Kong Stock Exchange (HKEX).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage